Treatment with interferon for genital HPV in HIV-positive and HIV-negative women. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment with interferon for genital HPV in HIV-positive and HIV-negative women.

Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):135-7. Unique Identifier : AIDSLINE MED/94252455
Semprini AE; Stillo A; Marcozzi S; Castagna C; Fiore S; Radaelli U; Department of Obstetrics and Gynecology, San Paolo Biomedical; Institute, University of Milan Medical School, Italy.

Abstract: The administration of interferons can be resorted to, either on its own or in combination with physical destruction methods, when the extent of genital HPV is widespread. Extensive genital HPV involvement is often seen in HIV-positive patients as a consequence of their immunodeficiency. The extension of these lesions may invalidate treatment by physical destruction, while an underlying immunodeficiency renders interferon therapy less efficacious. We studied HIV-positive and HIV-negative patients with a similar HPV involvement of their genital tract and compared the effectiveness of systemically administered alpha 2b and beta interferons in clearing HPV. Our results confirm that interferon therapy will cure most patients with extensive genital HPV when they are HIV-negative. HIV-positive patients with CD4 counts over 400 lymphocytes/mm3 may expect a similar cure rate, but this halves when this critical threshold is crossed. In these severely immunodeficient patients repeated courses of interferon therapy alone or in combination with physical destruction methods may be required to cure HPV infection.
Keywords: CD4-Positive T-Lymphocytes/PATHOLOGY Female Genital Diseases, Female/COMPLICATIONS/*THERAPY Human *HIV Seronegativity HIV Seropositivity/*COMPLICATIONS/PATHOLOGY Interferon-beta/*THERAPEUTIC USE Interferon-gamma, Recombinant/THERAPEUTIC USE Leukocyte Count Papovaviridae Infections/COMPLICATIONS/*THERAPY Tumor Virus Infections/COMPLICATIONS/*THERAPY JOURNAL ARTICLE

KWDcd4-positivet-lymphocytes/pathologyfemalegenitaldiseases,female/complications/KWDtherapyhumanKWDhivseronegativityhivseropositivity/KWDcomplications/pathologyinterferon-beta/KWDtherapeuticuseinterferon-gamma,recombinant/therapeuticuseleukocytecountpapovaviridaeinfections/complications/KWDtherapytumorvirusinfections/complications/KWDtherapyjournalarticle
940930
M9490204

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .